The CAR-T eligible patient population has more than doubled over the last three years, with new indications in autoimmune and solid cancers and approvals into earlier line treatments. In this webinar, experts explore ZS research into capacity, growth trends and outpatient challenges that many ex vivo gene therapies also face.
To date, community CAR-T use has been limited to highly sophisticated “community centers” with inpatient capabilities or that are affiliated to CAR-T centers. By solving both the operational and financial challenges community centers will face in administering CAR-T, we can fully unlock access to a fuller range of patients.
In this webinar, we discuss:
- How the over 80% increase in average CAR-T patients per treater compares to estimates
- Capacity challenges for centers looking to take on more patients
- The limits that protocols for outpatient adverse events place on treaters
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
